April 20, 2026 Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 20, 2026 FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
April 20, 2026 Quorum Cyber Warns Healthcare Sector to Brace for Identity-Based Attacks and Ransomware Surge
April 20, 2026 SilverBow Strategies Launches RFPArchon™, the First Product in Its Artemis AI Solutions™ Suite
